bacille Calmette-Guérin

(redirected from bacillus Calmette-Guerin)
Also found in: Medical, Encyclopedia.
Related to bacillus Calmette-Guerin: Bacillus Calmette-Guerin vaccine, Bacillus Calmette-Guérin

bacille Calmette-Guérin (BCG)

n bacilo de Calmette-Guérin (BCG)
Mentioned in ?
References in periodicals archive ?
Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade Ti transitional cell carcinoma.
Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.
The plot was created by comparing the variance with effect size in publications comparing the recurrence-free rate of patients receiving intravesical chemotherapy plus bacillus Calmette-Guerin (BCG) versus BCG alone.
MCNA is a biologic therapy developed to provide high risk non-muscle invasive bladder cancer patients who are refractory to or relapsing from front line therapy with bacillus Calmette-Guerin (BCG) with a therapeutic alternative to surgery.
Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy.
Jacobs and Margareta Tuckman report in the June 11 NATURE that they have designed a genetic-material-carrying "vehicle' called a shuttle phasmid that can enter bacillus Calmette-Guerin (BCG) mycobacteria.
To the Editor: Bacillus Calmette-Guerin (BCG) vaccine is one of the most commonly used vaccines for tuberculosis (TB) worldwide (1).
The model accounted for age, Bacillus Calmette-Guerin (BCG) vaccination and HIV infection.
Having read it from cover to cover, the Pontypridd lad was inspired to embark on a long career in palliative paediatric care, which would see him travel the Third World helping to administer the lifesaving bacillus Calmette-Guerin vaccine.
The latest vaccine, known as MVA85A, failed to protect babies who had already had the Bacillus Calmette-Guerin (BCG), the BBC reported.
Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder.
The Bacillus Calmette-Guerin (BCG) vaccine is offered to children at 10-14, but can be given to younger children at high risk of contact with tuberculosis.

Full browser ?